Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Impressive CYB003. Drysdale believes that what has been seen in its Phase 2 work on the development of this modified version of psilocin, the active agent in psilocybin, may have yielded the most impressive data in depression yet from a clinical study.</li><li>Thus, Cybin is approaching with excitement the more rigorous Phase 3 trial, which will involve a total pool of 550 patients with moderate to severe major depression disorder.</li><li>The trial is expected to start in the next few weeks.</li></ul>

Impressive CYB003. Drysdale believes that what has been seen in its Phase 2 work on the development of this modified version of psilocin, the active agent in psilocybin, may have yielded the most impressive data in depression yet from a clinical study.Thus, Cybin is approaching with excitement the more rigorous Phase 3 trial, which will involve a total pool of 550 patients with moderate to severe major depression disorder.The trial is expected to start in the next few weeks.

Cybin, Inc. - Potential of a Significant Paradigm Shift